We are live on ! Find out more
AP

Antipodes Partners Portfolio holdings

AUM $5.19B
1-Year Est. Return 36.17%
This Fund
S&P 500
This Quarter Est. Return
+12%
1 Year Est. Return
+36.17%
3 Year Est. Return
+104%
5 Year Est. Return
+169.34%
10 Year Est. Return
–
AUM
$3.22B
AUM Growth
+$31.1M
Cap. Flow
-$263M
Cap. Flow %
-8.15%
Top 10 Hldgs %
51.68%
Holding
124
New
21
Increased
40
Reduced
41
Closed
18

Top Buys

Rank Stock Value
1
WDAY icon
Workday
WDAY
+$79.2M
2
AMD icon
Advanced Micro Devices
AMD
+$76.5M
3
WLK icon
Westlake Corp
WLK
+$67.4M
4
EAT icon
Brinker International
EAT
+$48.5M
5
NU icon
Nu Holdings
NU
+$30M

Top Sells

Rank Stock Value
1
JD icon
JD.com
JD
+$121M
2
BEKE icon
KE Holdings
BEKE
+$88.9M
3
AA icon
Alcoa
AA
+$51.5M
4
CX icon
Cemex
CX
+$45.6M
5
ORCL icon
Oracle
ORCL
+$39.4M

Sector Composition

Rank Sector Weight
1 Technology 21.12%
2 Healthcare 17.28%
3 Financials 14.4%
4 Materials 12.43%
5 Consumer Discretionary 10.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMNM icon
76
Immunome
IMNM
$2.52B
$95.4K ﹤0.01%
10,261
-3,903
-28% -$32K
ESTA icon
77
Establishment Labs
ESTA
$2.72B
$87.5K ﹤0.01%
2,048
+73
+4% +$2.55K
CERT icon
78
Certara
CERT
$1.17B
$78K ﹤0.01%
6,665
+1,223
+22% +$14.5K
DXCM icon
79
DexCom
DXCM
$27.6B
$73.7K ﹤0.01%
844
-1,118
-57% -$87.6K
STE icon
80
Steris
STE
$20.9B
$62.5K ﹤0.01%
260
-273
-51% -$63.6K
COR icon
81
Cencora
COR
$60.3B
$61.2K ﹤0.01%
+204
New +$58.8K
GPCR icon
82
Structure Therapeutics
GPCR
$3.49B
$60.8K ﹤0.01%
2,932
-1,315
-31% -$28.9K
GE icon
83
GE Aerospace
GE
$367B
$59.5K ﹤0.01%
231
+28
+14% +$6.14K
ADSK icon
84
Autodesk
ADSK
$44.3B
$53.3K ﹤0.01%
172
+21
+14% +$5.96K
NTRA icon
85
Natera
NTRA
$37.5B
$52.9K ﹤0.01%
313
+30
+11% +$4.67K
ORIC icon
86
Oric Pharmaceuticals
ORIC
$1.25B
$52.7K ﹤0.01%
5,194
+1,372
+36% +$9.21K
LUMN icon
87
Lumen
LUMN
$6.53B
$49.9K ﹤0.01%
11,386
– –
MASS icon
88
908 Devices
MASS
$293M
$46.8K ﹤0.01%
6,558
+2,176
+50% +$12.1K
HSIC icon
89
Henry Schein
HSIC
$9.74B
$42.8K ﹤0.01%
+586
New +$40.3K
SGMT icon
90
Sagimet Biosciences
SGMT
$437M
$41.2K ﹤0.01%
+5,412
New +$22.8K
IRTC icon
91
iRhythm Holdings
IRTC
$3.59B
$39.3K ﹤0.01%
+255
New +$33K
SPRY icon
92
ARS Pharmaceuticals
SPRY
$590M
$38.4K ﹤0.01%
2,201
-742
-25% -$10.7K
NUVL
93
DELISTED
Nuvalent
NUVL
$36.5K ﹤0.01%
479
-61
-11% -$4.46K
IR icon
94
Ingersoll Rand
IR
$33B
$26K ﹤0.01%
313
+38
+14% +$3K
APGE icon
95
Apogee Therapeutics
APGE
$10.2B
$25.9K ﹤0.01%
597
+55
+10% +$2.09K
SDGR icon
96
Schrodinger
SDGR
$1.12B
$25.2K ﹤0.01%
1,252
-626
-33% -$14.3K
JANX icon
97
Janux Therapeutics
JANX
$935M
$24.2K ﹤0.01%
1,048
+416
+66% +$11K
CORZ icon
98
Core Scientific
CORZ
$7.23B
$23.7K ﹤0.01%
+1,391
New +$13.9K
NVCR icon
99
NovoCure
NVCR
$2.04B
$19.9K ﹤0.01%
+1,119
New +$19.5K
DAWN
100
DELISTED
Day One Biopharmaceuticals
DAWN
$19.5K ﹤0.01%
3,006
+963
+47% +$6.62K
1 2 3
4
5

Similar funds

MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
AUB
Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return
KACA
Kayne Anderson Capital Advisors Los Angeles, California $5.22B AUM 17.11% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
MIM
Merewether Investment Management Dallas, Texas $5.16B AUM 86.81% 1-Year Est. Return
AAI
Aequim Alternative Investments Mill Valley, California $5.16B AUM 9.8% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

Antipodes Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Antipodes Partners held 124 positions worth $3.22B, up 0.98% from $3.19B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Antipodes Partners withdrew a net $263M in Q2 2025, closing 18 positions and reducing 41 holdings. Its most notable exit was JD.com, an estimated $121M position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 15% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Antipodes Partners opened a new position in Workday worth $78M.

  • Antipodes Partners's largest Q2 2025 buy was Workday: 325,059 shares worth $78M.
  • Antipodes Partners added most to Nu Holdings in Q2 2025, an estimated $30M increase.
  • Antipodes Partners's biggest Q2 2025 reduction was Cemex, cutting an estimated $45.6M.
  • Antipodes Partners fully exited JD.com in Q2 2025, selling an estimated $121M.
  • Antipodes Partners's ten largest holdings make up 52% of its $3.22B portfolio in Q2 2025.
  • Antipodes Partners opened 21 new positions and closed 18 in Q2 2025.
  • Antipodes Partners's portfolio value rose 0.98% quarter-over-quarter to $3.22B.

Based on Antipodes Partners's 13F filing for Q2 2025, filed 5 Aug 2025.